Initiated clinical trial with novel nasal spray codenamed APR-AOS2020 in patients with mild COVID-19

Product recently cleared in EU as Class III medical device BALERNA, Switzerland, May 13, 2021 /PRNewswire/ -- APR Applied Pharma Research s.a. (APR), a leader in the development of pharmaceutica...

Full "IntellAsia: Resources" article